The National Institute of Allergy and Infectious Diseases has suspended a clinical trial on an HIV vaccine called HVTN 505. The clinical trial involved 2,500 participants and early data showed that those who received the vaccine were slightly more likely to contract HIV than those who had a placebo.
The NIAID confirmed the news in an official statement saying that they found a "non-statistically significant increase in HIV acquisition among volunteers in the investigational vaccine group compared to those in the placebo group," NIAID said in a statement.
The trial was based at New York's Columbia University and lead researcher said Dr. Scott Hammer explained:
"This is quite a substantial disappointment. We've learned from every clinical efficacy trial we've done. We've had good and bad news, but each one takes us a little closer in terms of what to pursue and not to pursue."
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.